Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) ...

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several ...

Basel, Switzerland Friday, April 4, 2025, 10:00 Hrs [IST] ...

(MENAFN- GlobeNewsWire - Nasdaq) Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...